Utah Medical Products, Inc.

UTMD Healthcare Medical Instruments & Supplies

Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024. In the quarter to June 2026, revenue fell 14.3%, EPS fell 10.6% and free cash flow fell 55.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

74.51 0.41 −0.55%
Market cap
$237.8M
P/E
22.7×
Fwd P/E
28.7×
Dividend yield
1.66%
F-score
6/9
Altman Z
36.25
Beneish M
−2.68
Dividend safety
82/100

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
38.52 40.90 50.22 52.28 49.05 42.18 46.90 42.00 41.41 39.30
Revenue Growth
(5.83%) (18.56%) (3.93%) 6.58% 16.30% (10.08%) 11.68% 1.41% 5.38% (2.14%)
Cost of Revenue
16.52 16.76 20.19 20.09 18.14 16.63 17.44 15.69 15.02 15.61
Gross Profit
22.00 24.14 30.04 32.20 30.92 25.55 29.47 26.31 26.40 23.69
R&D Expenses
0.67 0.81 0.56 0.49 0.53 0.49 0.48 0.45 0.45 0.48
SG&A Expenses
9.93 9.74 12.70 11.91 11.51 11.35 11.35 7.16 6.94 7.03
Operating Income
11.40 13.59 16.78 19.79 18.88 13.71 17.63 18.70 19.01 16.19
Non-operating Income/Expense
2.71 3.21 3.31 0.87 0.18 0.13 0.25 0.76 0.07 0.24
EBT
14.11 16.80 20.09 20.66 19.06 13.84 17.88 19.46 19.08 16.42
Income Tax Provision
2.82 2.93 3.45 4.19 4.27 3.04 3.16 0.90 10.58 4.29
Income after Tax
11.29 13.87 16.64 16.47 14.79 10.80 14.73 18.56 8.51 12.13
Dividends (Preferred)
0.00 0.00 — — 0.00 — 0.00 — 0.00 —
Net Income Common
11.29 13.87 16.64 16.47 14.79 10.80 14.73 18.56 8.51 12.13
EPS (Basic)
3.48 3.96 4.57 4.52 4.04 2.94 3.94 4.95 2.28 3.22
EPS (Diluted)
3.48 3.96 4.57 4.52 4.04 2.94 3.94 4.95 2.28 3.22
Shares (Basic, Weighted)
3.24 3.50 3.63 3.64 3.65 3.66 3.72 3.73 3.72 3.75
Shares (Diluted, Weighted)
3.24 3.50 3.64 3.64 3.66 3.67 3.74 3.75 3.74 3.77
Gross Margin
57.12% 59.03% 59.81% 61.58% 63.03% 60.57% 62.82% 62.64% 63.73% 60.28%
EBIT Margin
29.60% 33.23% 33.40% 37.85% 38.49% 32.50% 37.59% 44.52% 45.90% 41.19%
EBT margin
36.63% 41.08% 40.00% 39.52% 38.86% 32.81% 38.13% 46.33% 46.08% 41.79%
Net Profit Margin
29.30% 33.92% 33.12% 31.51% 30.15% 25.60% 31.40% 44.18% 20.54% 30.86%
Free Cash Flow Margin
37.18% 35.75% 43.09% 38.88% 42.10% 45.70% (9.56%) 41.18% 36.97% 28.57%
EBITDA
14.41 16.44 23.15 26.87 26.16 20.92 24.51 21.65 21.78 19.02
EBIT
11.40 13.59 16.78 19.79 18.88 13.71 17.63 18.70 19.01 16.19
Income from Continuous Operations
11.29 13.87 16.64 16.47 14.79 10.80 14.73 18.56 8.51 12.13
Consolidated Net Income/Loss
11.29 13.87 16.64 16.47 14.79 10.80 14.73 18.56 8.51 12.13
EPS (Basic, from Continuous Ops)
3.48 3.96 4.58 4.53 4.05 2.95 3.96 4.97 2.29 3.23
EPS (Basic, Consolidated)
3.48 3.96 4.58 4.53 4.05 2.95 3.96 4.97 2.29 3.23
EPS (Diluted, from Cont. Ops)
3.48 3.96 4.57 4.52 4.04 2.94 3.94 4.95 2.28 3.22
Shares (Diluted, Average)
3.24 3.50 3.64 3.64 3.66 3.67 3.74 3.75 3.74 3.77
EPS (Diluted, Consolidated)
3.48 3.96 4.57 4.52 4.04 2.94 3.94 4.95 2.28 3.22
EBITDA Margin
37.41% 40.19% 46.08% 51.40% 53.34% 49.59% 52.26% 51.56% 52.60% 48.40%
Operating Cash Flow Margin
38.14% 36.26% 44.36% 40.45% 43.22% 47.74% 36.36% 40.08% 40.83% 36.97%

Fold the line items

In millions of $ except per-share values · columns are period end dates